Yi‐Fang Tsai
-
- Cancer Genomics and Diagnostics 8
- Breast Cancer Treatment Studies 7
-
- HER2/EGFR in Cancer Research 13
- Cancer Cells and Metastasis 8
-
- PI3K/AKT/mTOR signaling in cancer 5
-
- Advanced Breast Cancer Therapies 8
-
- Chronic Lymphocytic Leukemia Research 5
- BRCA gene mutations in cancer 5
- Co-authors
- Ling‐Ming TsengJen‐Hwey ChiuChih‐Yi HsuChun‐Yu LiuJir‐You WangChu‐Wen YangPei‐Ju LienTa‐Chung Chao
- Journals
- Breast Cancer Research and Treatment (3 papers)Scientific Reports (2 papers)Cancer Research (2 papers)
- Partner nations
- TaiwanUnited States
In The Last Decade
Yi‐Fang Tsai
44 papers receiving 466 citations
Peers
Comparison fields: 5 of 83
- Cancer Research 123
- Oncology 173
- Molecular Biology 219
- Pulmonary and Respiratory Medicine 94
- Dermatology 21
Countries citing papers authored by Yi‐Fang Tsai
This map shows the geographic impact of Yi‐Fang Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi‐Fang Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi‐Fang Tsai more than expected).
Fields of papers citing papers by Yi‐Fang Tsai
This network shows the impact of papers produced by Yi‐Fang Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi‐Fang Tsai. The network helps show where Yi‐Fang Tsai may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yi‐Fang Tsai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 2 | |
| 2 | 2023 | 7 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 0 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 2 | |
| 8 | 2023 | 2 | |
| 9 | 2022 | 8 | |
| 10 | 2022 | 5 | |
| 11 | 2022 | 2 | |
| 12 | 2021 | 13 | |
| 13 | 2021 | 20 | |
| 14 | 2021 | 10 | |
| 15 | 2021 | 24 | |
| 16 | 2020 | 7 | |
| 17 | 2019 | 8 | |
| 18 | 2017 | 21 | |
| 19 | 2014 | 6 | |
| 20 | 2010 | 12 |
About Yi‐Fang Tsai
Yi‐Fang Tsai is a scholar working on Cancer Research, Oncology, Genetics, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 47 papers that have together received 473 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (13 papers), Cancer Cells and Metastasis (8 papers), Cancer Genomics and Diagnostics (8 papers), Advanced Breast Cancer Therapies (8 papers), Breast Cancer Treatment Studies (7 papers), Chronic Lymphocytic Leukemia Research (5 papers), BRCA gene mutations in cancer (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). The work is most often cited by research in Cancer Research (123 citations), Oncology (173 citations), Molecular Biology (219 citations), Pulmonary and Respiratory Medicine (94 citations) and Dermatology (21 citations). Yi‐Fang Tsai has collaborated with scholars based in Taiwan and United States. Frequent co-authors include Ling‐Ming Tseng, Jen‐Hwey Chiu, Chih‐Yi Hsu, Chun‐Yu Liu, Jir‐You Wang, Chu‐Wen Yang, Pei‐Ju Lien, Ta‐Chung Chao, Yi‐Ming Shyr and Chi‐Cheng Huang. Their work appears in journals such as Breast Cancer Research and Treatment, Scientific Reports, Cancer Research, Journal of Clinical Oncology and Journal of Pharmaceutical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.